Many patients don't reach targets despite implementation of latest bone disease guidelines

Nature Clinical Practice Nephrology 2, 471 (01 Sep 2006)

doi:10.1038/ncpneph0236 | Full Text | PDF

Cinacalcet for secondary hyperparathyroidism in ESRD patients

Nature Clinical Practice Nephrology 2, 8-9 (01 Jan 2006)

doi:10.1038/ncpneph0039 | Full Text | PDF

Does sevelamer have greater skeletal benefit than calcium carbonate in children with secondary hyperparathyroidism?

Tadao Akizawa

Nature Clinical Practice Nephrology 2, 130-131 (01 Mar 2006)

doi:10.1038/ncpneph0108 | Full Text | PDF

Does cinacalcet safely and effectively maintain long-term PTH control in secondary hyperparathyroidism?

Masafumi Fukagawa

Nature Clinical Practice Nephrology 2, 248-249 (01 May 2006)

doi:10.1038/ncpneph0154 | Full Text | PDF

Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney disease

Justin Silver and Ronen Levi

Kidney International 67, S8-S12 (01 Jun 2005)

doi:10.1111/j.1523-1755.2005.09501.x | Abstract | Full Text | PDF

An introduction to phosphate binders for the treatment of hyperphosphatemia in patients with chronic kidney disease

Eli A Friedman

Kidney International 68, S2-S6 (01 Jul 2005)

doi:10.1111/j.1523-1755.2005.00448.x | Abstract | Full Text | PDF

Phosphate binder therapy for attainment of K/DOQI™ bone metabolism guidelines

Charles R Nolan

Kidney International 68, S7-S14 (01 Jul 2005)

doi:10.1111/j.1523-1755.2005.00449.x | Abstract | Full Text | PDF

Drug Insight: renal indications of calcimimetics

Irina Shahapuni, Matthieu Monge, Roxana Oprisiu, Hakim Mazouz, Pierre-François Westeel, Philippe Moriniére, Ziad Massy, Gabriel Choukroun and Albert Fournier

Nature Clinical Practice Nephrology 2, 316-325 (01 Jun 2006)

doi:10.1038/ncpneph0191 | Full Text | PDF

Reappraisal of 2003 NKF-K/DOQI guidelines for management of hyperparathyroidism in chronic kidney disease patients

Matthieu Monge, Irina Shahapuni, Roxana Oprisiu, Najeh El Esper, Philippe Moriniére, Ziad Massy, Gabriel Choukroun and Albert Fournier

Nature Clinical Practice Nephrology 2, 326-336 (01 Jun 2006)

doi:10.1038/ncpneph0189 | Full Text | PDF

Guidelines for disorders of mineral metabolism and secondary hyperparathyroidism should not yet be modified

Joachim H Ix, L Darryl Quarles and Glenn M Chertow

Nature Clinical Practice Nephrology 2, 337-339 (01 Jun 2006)

doi:10.1038/ncpneph0190 | Full Text | PDF

Achieving NKF-K/DOQI™ bone metabolism and disease treatment goals with cinacalcet HCl

Sharon M Moe, Glenn M Chertow, Jack W Coburn, L Darryl Quarles, William G Goodman, Geoffrey A Block, Tilman B Drüeke, John Cunningham, Donald J Sherrard, Laura C McCary, Kurt A Olson, Stewart A Turner and Kevin J Martin

Kidney International 67, 760-771 (01 Feb 2005)

doi:10.1111/j.1523-1755.2005.67139.x | Abstract | Full Text | PDF

Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients

Shohei Nakanishi, Junichiro James Kazama, Tomoko Nii-Kono, Kentaro Omori, Takeyoshi Yamashita, Seiji Fukumoto, Fumitake Gejyo, Takashi Shigematsu and Masafumi Fukagawa

Kidney International 67, 1171-1178 (01 Mar 2005)

doi:10.1111/j.1523-1755.2005.00184.x | Abstract | Full Text | PDF

Pretreatment serum FGF-23 levels predict the efficacy of calcitriol therapy in dialysis patients

Junichiro J Kazama, Fuminori Sato, Kentaro Omori, Hitomi Hama, Suguru Yamamoto, Hiroki Maruyama, Ichiei Narita, Fumitake Gejyo, Takeyoshi Yamashita, Seiji Fukumoto and Masafumi Fukagawa

Kidney International 67, 1120-1125 (01 Mar 2005)

doi:10.1111/j.1523-1755.2005.00178.x | Abstract | Full Text | PDF

Progression of secondary hyperparathyroidism involves deregulation of genes related to DNA and RNA stability

Íñigo Santamaría, Daniel Álvarez-Hernández, Rosa Jofré, José Ramón Polo, Javier Menárguez and Jorge B Cannata-Andía

Kidney International 67, 2267-2279 (01 Jun 2005)

doi:10.1111/j.1523-1755.2005.00330.x | Abstract | Full Text | PDF

Calcimimetics: A new tool for management of hyperparathyroidism and renal osteodystrophy in patients with chronic kidney disease

Jill S Lindberg

Kidney International 67, S33-S36 (01 Jun 2005)

doi:10.1111/j.1523-1755.2005.09505.x | Abstract | Full Text | PDF

Cinacalcet HCl: A novel treatment for secondary hyperparathyroidism in stage 5 chronic kidney disease

L Darryl Quarles

Kidney International 68, S24-S28 (01 Jun 2005)

doi:10.1111/j.1523-1755.2005.00451.x | Abstract | Full Text | PDF

Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism

Pierre D'Amour, Jean-Hugues Brossard, Louise Rousseau, Loan Nguyen-Yamamoto, Edgard Nassif, Claude Lazure, Dany Gauthier, Jeffrey R Lavigne and Richard J Zahradnik

Kidney International 68, 998-1007 (01 Sep 2005)

doi:10.1111/j.1523-1755.2005.00493.x | Abstract | Full Text | PDF

First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl

Kevin J Martin, Harald Jüppner, Donald J Sherrard, William G Goodman, Mark R Kaplan, George Nassar, Patricia Campbell, Mario Curzi, Chaim C Harytan, Laura C McCary, Matthew D Guo, Stewart A Turner and David A Bushinsky

Kidney International 68, 1236-1243 (01 Sep 2005)

doi:10.1111/j.1523-1755.2005.00517.x | Abstract | Full Text | PDF

Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism

John Cunningham, Mark Danese, Kurt Olson, Preston Klassen and Glenn M Chertow

Kidney International 68, 1793-1800 (01 Oct 2005)

doi:10.1111/j.1523-1755.2005.00596.x | Abstract | Full Text | PDF

Opportunity and cost of sevelamer in dialysis patients

Ghazali Abderrhamane, Demontis Renato and Fievet Patrick

Kidney International 67, 1636 (01 Apr 2005)

doi:10.1111/j.1523-1755.2005.247_5.x | Abstract | Full Text | PDF

Economic impact of sevelamer in patients with ESRD

Wajeh Y Qunibi and Charles R Nolan

Kidney International 67, 1636-1637 (01 Apr 2005)

doi:10.1111/j.1523-1755.2005.247_6.x | Abstract | Full Text | PDF

High dialysate calcium may improve the efficacy of calcimimetic treatment in hemodialysis patients with severe secondary hyperparathyroidism

Malik Touam, Victorio Menoyo, David Attaf, Henri-Emile Thebaud and Tilman B Drüeke

Kidney International 67, 2065 (01 May 2005)

doi:10.1111/j.1523-1755.2005.310_1.x | Abstract | Full Text | PDF

Reply from the Authors

Kidney International 67, 2065-2066 (01 May 2005)

doi:10.1111/j.1523-1755.2005.310_2.x | Full Text | PDF

Active vitamin D agents and refractory hyperparathyroidism in dialysis patients

Carlo Basile and Carlo Lomonte

Kidney International 68, 410 (01 Jul 2005)

doi:10.1038/sj.ki.4496106 | Abstract | Full Text | PDF

Reply from the Authors

Kidney International 68, 410-411 (01 Jul 2005)

doi:10.1038/sj.ki.4496107 | Full Text | PDF

Immunosuppressive and calcimimetic drug–drug interactions

Hassane Izzedine, Vincent Launay-Vacher, Svetlana Karie and Gilbert Deray

Kidney International 68, 1903-1904 (01 Oct 2005)

doi:10.1111/j.1523-1755.2005.00578.x | Abstract | Full Text | PDF